See also separate entries for sofosbuvir and sofosbuvir & velpatasvir.
- TRADE NAME: Vosevi (Gilead)
- INDICATIONS: Chronic HCV infection
- CLASS: Direct-acting antiviral, Hepatitis C virus NS3/4A protease inhibitor (voxilaprevir), Hepatitis C virus NS5A inhibitor (velpatasvir), Hepatitis C virus nucleotide analog NS5B polymerase inhibitor (sofosbuvir)
- HALF-LIFE: <29 hours (sofosbuvir); 17 hours (velpatasvir); 33 hours (voxilaprevir)
- FDA APPROVAL DATE: 07/18/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Atazanavir, Carbamazepine, Cyclosporine, Efavirenz, Lopinavir, Oxcarbazepine, Phenobarbital, Phenytoin, Pitavastatin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Rosuvastatin, St John's Wort, Tipranavir - PREGNANCY: Insufficient evidence to inform drug-associated risk
- See adverse reactions attributed to class:
RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
